Valuation: ORIC Pharmaceuticals, Inc.

Market Cap 1.2B 1.05B 967M 902M 1.71B 115B 1.74B 11.64B 4.51B 56.26B 4.52B 4.43B 194B P/E 2026 *
-7.99x
P/E 2027 * -7.24x
Enterprise Value 1.1B 957M 879M 820M 1.55B 104B 1.58B 10.58B 4.1B 51.16B 4.11B 4.02B 176B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.15%
Yield 2026 *
-
Yield 2027 * -
1 day+6.89%
1 week+23.04%
Current month+7.48%
1 month+52.76%
3 months+30.93%
6 months+42.47%
Current year+42.30%
1 week 9.47
Extreme 9.47
11.67
1 month 7.36
Extreme 7.355
11.67
Current year 7.23
Extreme 7.23
14.25
1 year 7.23
Extreme 7.23
14.93
3 years 3.9
Extreme 3.8951
16.65
5 years 2.36
Extreme 2.36
26.7
10 years 2.36
Extreme 2.36
40.81
Manager TitleAgeSince
Chief Executive Officer 47 2018-05-06
Director of Finance/CFO 52 2019-08-31
Chief Tech/Sci/R&D Officer - 2025-08-17
Director TitleAgeSince
Chairman 68 2018-03-06
Director/Board Member 47 2018-05-06
Director/Board Member 62 2020-01-31
Date Insider Type Main position Quantity % Market Cap.
02-23Fiscal year

Chief Financial Officer

156,000 0.1602%
01-15Sell

Founder

6,700 0.0069%
01-01Free

Chief Executive Officer

787,500 0.8086%
Change 5-day change 1-year change 3-year change Capi.($)
+6.89%+23.04%+9.30%+50.00% 1.2B
-0.87%+4.28%+77.67%+134.12% 58.73B
-3.12%+3.48%+72.79%+94.67% 53.92B
+3.86%+8.38%-9.90%-9.62% 24.67B
+4.30%+6.82%+13.60%+428.91% 24.19B
+4.74%+13.68%+45.58%-1.42% 18.8B
-0.85%+9.17%+43.81%-28.35% 17.61B
+2.57%+16.74%+171.12%+355.99% 16.25B
+3.50%+4.92%+26.07%+192.26% 14.04B
+6.72%+19.38%+42.82% - 13.9B
Average +2.77%+10.27%+49.29%+135.17% 24.33B
Weighted average by Cap. +1.01%+7.29%+57.35%+135.73%

Financials

2026 *2027 *
Net sales - -
Net income -156M -137M -125M -117M -222M -14.88B -225M -1.51B -585M -7.3B -587M -574M -25.14B -190M -166M -152M -142M -269M -18.05B -274M -1.83B -710M -8.85B -712M -697M -30.51B
Net Debt -109M -95.53M -87.72M -81.8M -155M -10.41B -158M -1.06B -409M -5.1B -410M -402M -17.59B -231M -202M -186M -173M -328M -22.02B -334M -2.23B -866M -10.8B -869M -850M -37.22B
Logo ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Employees
104
Date Price Change Volume
26-07-02 US$11.64 +6.89% 2,174,162
26-07-01 US$10.89 +0.55% 1,622,570
26-06-30 US$10.83 +6.65% 1,665,494
26-06-29 US$10.16 +6.56% 1,123,898
26-06-26 US$9.530 +0.74% 3,762,524
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
11.64USD
Average target price
20.29USD
Spread / Average Target
+74.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ORIC Stock